Company / Revenue
Sunshine Biopharma Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$34.9M
FY2025
5-year range
$71.4K / $34.9M
FY2021-FY2025
Trend
+44.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has increased for 6 consecutive years, from $0 in FY2019 to $35M in FY2025.
Based on SEC 10-K filings.
$35M in FY2025 with a 5-year CAGR of +340.1%.
Improved from $4M to $35M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +434.5%
- 5-Year CAGR
- +340.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Sunshine Biopharma Inc.'s revenue has grown for 5 consecutive years.
- 5-year CAGR of +340.1%, indicating consistent growth.
- In FY2025, revenue increased 44.7% year-over-year.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.9M | +44.7% |
| FY2024 | $24.1M | +454.4% |
| FY2023 | $4.3M | +1802.4% |
| FY2022 | $228.4K | +219.9% |
| FY2021 | $71.4K | +238.1% |
| FY2020 | $21.1K | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | $0 | -100.0% |
| FY2016 | $1.7K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026